<DOC>
	<DOCNO>NCT01374425</DOCNO>
	<brief_summary>This randomize , open-label , multicenter , Phase II study primary objective ass whether expression select chemotherapy marker associate progression-free survival ( PFS ) participant treat bevacizumab plus leucovorin , 5-fluorouracil , oxaliplatin ( mFOLFOX6 ) bevacizumab plus leucovorin , 5-fluorouracil , irinotecan ( FOLFIRI ) . The study population consist participant first-line mCRC .</brief_summary>
	<brief_title>Study Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification Participants With Previously Untreated Metastatic Colorectal Cancer ( mCRC )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically confirm colorectal cancer ( CRC ) least one measurable metastatic lesion RECIST Version 1.1 Archival tumor tissue sample must request available prior study entry . If archival tumor tissue sample available , fresh biopsy tissue sample must obtain discuss first medical monitor . A copy local pathology report must submit along specimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Participants treat brain metastasis eligible study participation . Participants may receive ongoing treatment steroid Screening . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may wholebrain radiotherapy , radiosurgery , neurosurgery , combination deem appropriate treating physician . Radiotherapy stereotactic radiosurgery must complete least 28 day prior randomization . Female participant pregnant breastfeeding . Female participant childbearing potential agree use effective , nonhormonal mean contraception study period least 6 month follow last administration study drug . Female participant intact uterus ( unless amenorrheic last 24 month ) must negative serum pregnancy test within 7 day prior randomization study . Male participant must agree use effective contraception study period least 6 month follow last administration study drug , even surgically sterilize . Any prior systemic treatment mCRC Adjuvant chemotherapy CRC complete &lt; 12 month Evidence Gilbert 's syndrome homozygosity UGT1A1*28 allele Known positivity human immunodeficiency virus ( HIV ) Malignancies mCRC within 5 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent Radiotherapy site reason within 28 day prior randomization , except palliative radiotherapy bone lesion within 14 day prior randomization Clinically detectable thirdspace fluid collection control drainage procedure prior study entry Treatment investigational agent , participation another investigational drug trial within 28 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>